Fortnightly TAG Mail – resources list 29th October 2026

NSW TAG ACTIVITIES

Updated NSW TAG publication
Know Your Insulins poster v3 Oct 2026- has incorporated new product and latest TGA advice re discontinuations- link

Recent Email Discussions:
Processes for out-of-session (OOS) IPU decision-making
Governance of Medicine Access Programs: How do DTCs manage MAPs?

TAG Mail
Searching Cumulative TAG Mail listings: Remember to search Cumulative TAG Mail listings, which are collated in 6 months batches from 2023. These cumulative listings are useful to survey whenever you have a medicine or condition you wish to explore as TAG mail covers the grey literature as well as the traditional academic literature. Just 'Control F' relevant terms to search for your query.

Contact Sasha Bennett at sasha.bennett@svha.org.au for information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS *highlighted with relevant NSW TAG and CATAG resources*

AJHP: Pharmacist-led preoperative medication management on elective surgical cancellation rates and economic implications - link CATAG MAIA Perioperative management of SGLT2 inhibitors and GLP-1 receptor agonists practice tool
AJHP: Pharmacist role in transforming Alzheimer's care: Anti-amyloid therapy experience- link
Cochrane: Pharmaceutical industry information and promotional strategies aimed at prescribers - link NSW TAG resource CATAG Managing medicine samples
Cochrane: Letter to the editor: Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease - link
DOM: Cardiorenal Efficacy and Safety of SGLT2is and Finerenone in CKD with T2DM - link
DTB: Using genomics to personalise prescribing - link
EJHP: Post hoc analysis of pharmacist medication recommendations at discharge in geriatric inpatients - link NSW TAG Polypharmacy Resources and Deprescribing Tools CATAG MAIA Assessing the hidden risk of cumulative medicines toolkit
EJHP: Prescribing quality, documentation and opportunities for antithrombosis stewardship - link
IMJ:- Editorial: Is mainstreaming the answer? Genomics in practice or practising genomics - link
IMJ: Medical emergency response related to MedicAtion InciDents (MERRMAID) - link
IJQHC: FAME Analysis of the In-Hospital Medication Process: Identification of Systemic Risks and development of Improvement strategies - link NSW TAG QUM Indicators
IJQHC: Study on targeted double checks in parenteral medication administration - link
ISMP Canada: Advancing Appropriate Use of Antipsychotic Medications in Long-Term Care - link MEGA-MAC Indicators
JAMA: From Biological Insight to a New Class of Medicines for Hemophilia A - link
JAMA: The Orexin System—A Key Component of Sleep Regulatory Networks and Involvement in Narcolepsy - link NSW TAG Sleep Toolkit
JAMA IM: Communicating Uncertainties About the Benefits and Risks of New Cancer Drugs - link CATAG Emerging Medicines Guide
JACI: Guidelines for the management of adult penicillin allergy in community and specialist settings in Australia and New Zealand - link
JACC: Optimizing Blood Pressure Care in Patients with Resistant Hypertension - link
NHMRC Impact Case Studies: Preventing paracetamol overdose – 21 October NSW TAG IV Paracetamol Use
Paed QS: Quality Improvement Initiative to Reduce Medication-induced Kidney Injury – link CATAG MAIA Medicines and the Kidney toolkit

P'therapy: A Model for Estimating the Risk of Gastrointestinal Bleeding for Patients on Oral Anticoagulants and Interacting Medications - link CATAG MAIA Assessing the hidden risk of cumulative medicines toolkit

OTHER NEWS

NSW Health
- Nurse practitioners and prescribing of psychostimulant medicines - link
- Preventing and minimising restrictive practices in NSW Health settings (PD2026_055)

TGA
- TGA strengthening sunscreen regulation to improve confidence in Sun Protection Factor (SPF) claims - link

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation, NSW (ACI)
The latest weekly Evidence Digest can be found here

Australian Institute of Health and Welfare (AIHW)
- Health expenditure Australia 2024–25 – link
- Health system spending on disease and injury in Australia 2024–25 - link

NHMRC Impact Case Studies
- Preventing paracetamol overdose – 21 October

PBS
- Review of low-cost PBS-listed antidepressants - 28 October 2026

Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG)
- Management of Vasomotor and Genitourinary Symptoms of Menopause (C-Gyn 9) Guideline - link

TGA
- Database of section 19A approvals to import and supply medicines to address medicine shortages
- AusPARs:
-- Jaypirca (pirtobrutinib) is approved for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
-- Wainua (eplontersen) is approved for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adults with stage 1 or stage 2 polyneuropathy
- Australian prescription medicine decision summaries:
-- Aflivu and Ahzantive (aflibercept) or wet age-related macular degeneration, macular oedema secondary to central retinal vein occlusion and branch retinal vein occlusion, diabetic macular oedema, and myopic choroidal neovascularisation
-- MS-2 Step (mifepristone and misoprostol) - extension of the current indication for the medical termination of an intrauterine pregnancy from up to 63 days' gestation to up to 70 days' gestation; new indication for the medical management of missed miscarriage up to 70 days' gestation, determined by ultrasound equivalence rather than menstrual period
-- Simulara, Solentis and Zivra (ranibizumab) for neovascular (wet) age-related macular degeneration, visual impairment due to diabetic macular oedema, proliferative diabetic retinopathy, visual impairment due to choroidal neovascularisation, visual impairment due to choroidal neovascularisation secondary to pathologic myopia, visual impairment due to macular oedema secondary to retinal vein occlusion

REPORTS AND PUBLICATIONS – INTERNATIONAL

British National Formulary
- BNF + BNFC Knowledge Updates – October 2026

Canadian Agency for Drugs and Technologies in Health
- Outpatient Parenteral Antibiotic Therapy - link

electronic Medicines Compendium (eMC) (UK)
- New products
-- Dyrupeg (pegfilgrastim) 6 mg solution for injection in a pre-filled syringe - for reduction in the duration of neutropenia and the incidence of febrile neutropenia in adults treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes)
-- Zefylti (filgrastim) solution for injection/infusion in pre-filled syringe - biosimilar to Neupogen for the treatment of neutropenia and the mobilisation of peripheral blood progenitor cells. It is available as 30 MU/0.5ml and 48 MU/0.5ml solution for injection or infusion in pre-filled syringe
- New indications
-- Gobivaz (golimumab) - now indicated in combination with methotrexate for treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with methotrexate
-- Keytruda (pembrolizumab) - resectable muscle invasive bladder cancer indication revised to a single cisplatin-agnostic indication based on Keynote-B15 and 905 studies

European Medicines Agency (EMA)
- European CHMP recommendations for the EU – October 2026
-- for approval of 6 new medicines, including 2 biosimilars and one hybrid (daraxonrasib, orforglipron, navepegritide, temozolomide, Fovlussea (ranibizumab biosimilar) and Neuzafy (filgrastim biosimilar))
-- for extending/amending license indications for 5 medicines (pandemic influenza vaccine H5N1 AstraZeneca, insulin icodec/semaglutide, talquetamab, olezarsen, and tucatinib)
-- Refuses marketing authorization for narsoplimab (Yartemlea) for hematopoietic stem cell transplant (HSCT)-associated thrombotic microangiopathy (TA-TMA).The monoclonal antibody was intended for adults and children aged 2 years or older with high-risk TA-TMA - link

Food and Drug Administration (FDA) USA
- New Drug approvals
-- Awiqli (insulin icodec-abae), First once-weekly insulin for paediatric Type 2 Diabetes Mellitus
-- Brytly (apraclonidine) nonprescription eye drop for relief of eye redness – PI-label
-- Climara Pro (estradiol and levonorgestrel transdermal system), once-weekly generic hormone therapy patch for women
-- Hibsago (bepirovirsen) to treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy – PI-label
-- Jemperli (dostarlimab-gxly), immunotherapy that may allow certain patients with rectal cancer to avoid chemotherapy, radiation and surgery
-- Ryzumvi eye drops for presbyopia
-- talazoparib (Talzenna) with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations

Health Foundation UK
- AI in health care is changing what we mean by risk - link

Medicines and Healthcare products Regulatory Agency (MHRA)
- Authorises plozasiran (Redemplo) for adults with familial chylomicronaemia syndrome - link
- Approves icotrokinra hydrochloride (Icotyde) for moderate to severe plaque psoriasis - link

Monthly Index of Medical Specialities (MIMS) UK
- 1mg dose of EURneffy nasal adrenaline spray now available for UK prescribing - link
- Fire-retardant emollient, Novamol Protect, now available in UK - link

NHS England
- Tirzepatide (Mounjaro®) for managing obesity – patient leaflet

National Institute for Health and Care Excellence (NICE) UK
- Insulin efsitora alfa for treating type 2 diabetes (TA1200)
- Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more lines of anti-HER2 treatment (TA1202)
- Olezarsen for treating familial chylomicronaemia syndrome (TA1203)
- Plozasiran for treating familial chylomicronaemia syndrome (TA1204)

UK Health Security Agency
- Influenza: treatment and prophylaxis using anti-viral agents - update

World Health Organisation (WHO)
- Guideline on the integrated management of obesity in children – link
- Guideline on the integrated management of obesity in adolescents - link
- Global roadmap for hypertensive disorders of pregnancy from 2026 to 2035 and beyond - link
- Target regimen profiles for long-acting injectables for tuberculosis prevention and treatment - link
- Tobacco and infertility - link

MEDICATION SAFETY

electronic Medicines Compendium (eMC) (UK)
- Revised SPCs
-- Besponsa (inotuzumab ozogamicin) - information on its use as monotherapy in paediatric patients and to clarify that to mitigate the risk of QT prolongation, the time of infusion should be increased to 1.5 hours in paediatric patients with a body weight <35 kg
-- Bevespi Aerosphere (formoterol fumarate dihydrate, glycopyrronium bromide) - as with other inhalation therapies, administration may result in paradoxical bronchospasm, which can be life-threatening
-- Eltroxin (levothyroxine sodium) - new interaction warning on the concurrent consumption of fibre supplements or fibre-containing medicinal products, as levothyroxine absorption could be reduced. Monitoring of thyroid function and dose adjustment may be required with concurrent use
-- Imdylltra (tarlatamab) - Monitoring requirements for cycle 1 updated to advise that patients should be monitored from the start of the infusion for 6 to 8 hours on days 1 & 8; additional monitoring, including monitoring after subsequent infusions, is at the discretion of the healthcare professional
-- Lipitor (atorvastatin) - although interaction studies with atorvastatin and colchicine have not been conducted, cases of myopathy have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribed together
-- Salazopyrin (sulfasalazine) - should not be administered concurrently with methenamine hippurate because of the risk of crystalluria
-- Sudafed (xylometazoline hydrochloride) Blocked Nose Spray should not be used for more than five (previously seven) consecutive days, and that at least 8 hours should be left between doses. Prolonged or excessive use may result in rhinitis medicamentosa and atrophy of the nasal mucosa
-- Scemblix (asciminib) - information on the drug-drug interactions of asciminib with BCRP and P-gp substrates updated, based on the results from a study with rosuvastatin and digoxin
-- Sinemet (carbidopa , levodopa) tablets – vitamin B6 deficiency as a common ADR, and warning of increased seizure risk from B6 deficiency, particularly with high doses and poor nutrition. Monitor levels and supplement pyridoxine in high-dose carbidopa/levodopa patients or those with suggestive symptoms
-- Transtec (buprenorphine) - seizures added as ADR of unknown frequency. SPC notes Transtec® has not been evaluated in patients with seizure disorder (SD), but like other analgesics with mu-opioid receptor agonist activity, buprenorphine may lower seizure threshold in patients with history of SD
-- Winrevair (sotatercept) - Thrombocytopenia reported more frequently in patients receiving prostacyclin infusion (7.7% to 24.5%) vs not receiving prostacyclin infusion (0.0% to 3.7%). GI tract bleeding added as a 'very common' ADR; colonic angioectasia & skin hypopigmentation added as 'common' ADRs
-- Zilbrysq (zilucoplan sodium) - increases susceptibility to meningococcal and other Neisseria infections. Advice is given regarding vaccinations, and prophylactic antibiotic treatment (where

appropriate). Patients should be counselled on this risk & monitored for signs of infection during treatment
- Risk minimisation materials
-- Remsima 100mg and 350mg concentrate for solution for infusion, a new IV formulation of infliximab. Letter advises of the risk of serious metabolic harm in patients with hereditary fructose intolerance, due to the sorbitol content (45mg per mL)
-- Caspofungin: use of polyacrylonitrile (PAN) membranes during continuous renal replacement therapy (CRRT). Letter contains recommendations for healthcare professionals related to the possibility that (PAN)-based membranes used in CRRT may adsorb caspofungin, potentially reducing systemic exposure and treatment effectiveness
-- Fabhalta (iptacopan) – confirmation of vaccine and/or antibiotic prophylaxis form (PNH indication) - Iptacopan can only be dispensed once Novartis receives written confirmation that each patient has received vaccination against N. meningitidis and S. pneumoniae infections and/or receipt of prophylactic antibiotic treatment
-- Remsima Liquid (infliximab concentrate for solution for infusion): Patient Reminder Card contains important safety information, including its contra-indication in people with hereditary fructose intolerance, and warnings regarding infection, pregnancy, breastfeeding and vaccinations

ISMP Canada – Safety Bulletins
- Advancing Appropriate Use of Antipsychotic Medications in Long-Term Care: Collaborative Action Needed across the Health Care System - link

Medicines and Healthcare products Regulatory Agency (MHRA) UK
- MHRA safety roundup: October 2026 includes:
-- IXCHIQ Chikungunya vaccine: UK marketing authorisation withdrawn following safety review - link
-- #MedSafetyWeek (2 to 8 November 2026): Don't ignore suspected side effects, report them! Updates to the Yellow Card website and app - link

TGA
- Updates to the Prescribing Medicines in Pregnancy database - October 2026
- Information about major medicine shortages – link
-- About the shortage of methylphenidate hydrochloride products - link
-- About the changes to the supply of insulin products - link
-- About the shortage of Creon (pancreatic extract) capsules - link
-- About the shortage of transdermal HRT patches - link

PAPERS OF INTEREST

American Journal of Health-System Pharmacy (AJHP)
- Effect of pharmacist-led preoperative medication management on elective surgical cancellation rates and economic implications - link
- Vial puncture mechanics with a mechanical assist device during anticancer drug compounding with a closed-system drug transfer device - link
- Micronutrient deficiencies in continuous renal replacement therapy: A literature review and the emerging role of the pharmacist - link
- Pharmacy performance evaluation: A single-center assessment of drug waste and mitigation strategies - link
- Pharmacist role in transforming Alzheimer's care: Anti-amyloid therapy experience at Vanderbilt University Medical Center - link
- Physical Simulated Y-Site Compatibility of Hypertonic Saline with Vasoactive Medications Commonly Used in Pediatric Intensive Care - link
- Upadacitinib and Warfarin Drug Interaction Resulting in Significantly Increased International Normalized Ratio: A Case Report and Review of the Literature - link
- Assessing Medication Confounders Before Determination of Brain Death/Death by Neurologic Criteria: A Primer, with Opioids as a Worked Example - link
- Symptom-monitored loading: An evaluation of prophylactic medications in patients with severe alcohol withdrawal - link

- An Evaluation of Insulin Use in Hospitalized Patients with Corticosteroid-Related Hyperglycemia - link
- Postoperative length of stay comparison associated with a switch from alvimopan to naloxegol in patients undergoing major small and large bowel procedures - link

Annals of Internal Medicine
- Periconception Parental Red Blood Cell Folate, Vitamin B12, and Birth Defects in Offspring: A Prospective Cohort Study - link
- Bemotrizinol Approval: A Step Toward U.S. Sunscreen Modernization - link
- Iron Deficiency in Women: A Silent Pandemic with Consequences That May Reach the Classroom - link
- Management of Menopausal Symptoms - link
- Obesity and Cancer Risk in Young Adults in Korea: A Nationwide Health Screening Cohort Study - link

Arthritis & Rheumatology
- Oral Glucocorticoid Dose Patterns and Organ Damage in Systemic Lupus Erythematosus—A Nationwide Cohort Study - link
- Higher risk of Long COVID among patients with autoimmune rheumatic diseases and immunomodulatory therapy: a retrospective cohort analysis of national US data - link
- Treatment Approaches to Macrophage Activation Syndrome in Real Life and Priorities for Future Research: Results from the International METAPHOR Project - link
- Comparative risks of mortality and fractures in patients with osteoarthritis initiating tramadol versus other opioids - link

Blood Advances
- American Society of Hematology 2026 guidelines for diagnosis of iron deficiency - link

British Journal of Clinical Pharmacology
- Drug repurposing in fibrosis: From molecular networks to antifibrotic therapeutics—A narrative review - link
- Cardiovascular outcomes of SGLT2 inhibitors across the spectrum of myocardial infarction: A systematic review and meta-analysis - link
- Analysis of queries in an HIV drug–drug interaction checker to explore changes in prescribing patterns: A 5-year analysis - link

British Journal of General Practice
- Non-antibiotic interventions to prevent recurrent urinary tract infections in women: overview of systematic reviews of randomised controlled trials - link

British Journal of Obstetrics and Gynaecology
- Efficacy and Safety of Lidocaine Compared to Other Agents for Intrauterine Device Insertion Pain: A Systematic Review and Meta-Analysis - link

BMC Medicine
- Left atrial appendage occlusion versus oral anticoagulation in atrial fibrillation: a meta-analysis of randomized controlled trials - link

British Medical Journal (BMJ)
- Bat-borne zoonoses: transmission, impact, prevention, and management - link
- GLP-1s and criminality: US trial will test whether semaglutide can fight crime - link
- Extreme weather events: A practical guide for clinicians - link
- Advances in the management of renal cell carcinoma - link

Circulation
- Consensus Guidance for the Female-Specific Prevention and Management of Cardiovascular Disease: A US Scientific Statement - link

Cochrane
- Pharmaceutical industry information and promotional strategies aimed at prescribers - link
- Letter to the editor: Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease - link

Diabetes, Obesity and Metabolism
- Comparative Cardiorenal Efficacy and Safety of SGLT2 Inhibitors and Finerenone in Chronic Kidney Disease with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis - link
- Effects of a Low-Carbohydrate Diet Combined with Exercise on HbA1c in Adults With Type 2 Diabetes: A Bayesian Multilevel Network and Dose–Response Meta-Analysis - link
- SGLT2 Inhibitors Reduce Heart Failure Hospitalization, Cardiovascular Death and Kidney Outcomes in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials - link

Drug and Therapeutics Bulletin
- Using genomics to personalise prescribing - link
- Lipid-lowering for people with chronic kidney disease: a narrative review - link

EClinical Medicine
- Adalimumab versus placebo as add-on to standard therapy for non-infectious uveitis in the United Kingdom: the ASTUTE randomised controlled trial with treatment run-in - link

European Heart Journal
- Acute heart failure in emergency settings: A clinical consensus statement of the Association for Acute CardioVascular Care and the Heart Failure Association of the European Society of Cardiology and the European Society for Emergency Medicine - link
- Sex differences in cardiovascular disease burden, risk factors, and disease spectrum in Europe: a global burden of disease 2023 analysis within the ESC Atlas framework - link

European Journal of Hospital Pharmacy
- Now or never: a post hoc analysis of pharmacist medication recommendations at discharge in geriatric inpatients from the ASPIRE trial - link
- Pharmacist-led renal medication safety and stewardship practices in adults with kidney disease: a scoping review - link
- Combination antiplatelet and anticoagulant therapy in general internal medicine: prescribing quality, documentation and opportunities for antithrombosis stewardship - link

Internal Medicine Journal
- Editorial: Is mainstreaming the answer? Genomics in practice or practising genomics - link
- Medical emergency response related to MedicAtion InciDents (MERRMAID): a case series and lessons to improve medication safety - link

International Journal for Quality in Health Care
- Failure Mode and Effects Analysis of the In-Hospital Medication Process: Identification of Systemic Risks and development of Improvement strategies - link
- Targeting what matters: a quasi-experimental controlled before-and-after study on targeted double checks in parenteral medication administration - link

JAMA
- What Is Alcohol-Related Liver Disease? - link
- From Biological Insight to a New Class of Medicines for Hemophilia A: The 2026 Lasker-DeBakey Clinical Medical Research Award - link
- The Orexin System—A Key Component of Sleep Regulatory Networks and Involvement in Narcolepsy: The 2026 Albert Lasker Basic Medical Research Award - link
- Effect of Vasopressin Initiation Threshold on Septic Shock Mortality: The VASSPR Cluster Crossover Randomized Strategy Trial - link
- Fluid Therapy in Mechanically Ventilated Critically Ill Adult Patients - link

- Intraoperative Dobutamine Plus Norepinephrine to Prevent Postoperative Acute Kidney Injury in Septic Shock: A Randomized Clinical Trial - link
- Isoflurane-Based Inhaled Sedation in Mechanically Ventilated Adults with Acute Hypoxemic Respiratory Failure: The SAVE-ICU Randomized Clinical Trial - link
- Therapy for Adults with Complicated Urinary Tract Infection - link
- Childhood Cancer Risk After Assisted Reproductive Technology – link
- Obesity in Children Aged 2 to 12 Years: A Review - link
- JAMA Patient Page: What Is Celiac Disease? - link
- Rituximab vs Azathioprine for Eosinophilic Granulomatosis with Polyangiitis Maintenance Therapy: A Randomized Clinical Trial - link
- Sodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials - link
- Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial – link
- Testosterone Use Rises Among Women, but Does the Evidence Support It? – link
- Preoperative Intranasal Oxytocin and Probable Acute Stress Disorder After Traumatic Fracture Surgery: A Randomized Clinical Trial - link

JAMA Cardiology
- Intensive vs Standard Blood Pressure Lowering in People with and without Chronic Kidney Disease: A Systematic Review and Meta-Analysis - link

JAMA Internal Medicine
- Communicating Uncertainties About the Benefits and Risks of New Cancer Drugs: Two Randomized Clinical Trials - link
- Preoperative Medicine for the Internal Medicine Clinician - link

JAMA Network Open
- Mortality Among People with Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis - link

JAMA Neurology
- Early Pregnancy Use of Anti-CGRP Monoclonal Antibodies and Propranolol and Spontaneous Abortion Risk - link

Journal of Allergy and Clinical Immunology
- Guidelines for the management of adult penicillin allergy in community and specialist settings in Australia and New Zealand: An AGREE II and Delphi-based approach - link

Journal of the American College of Cardiology
- Optimizing Blood Pressure Care in Patients with Resistant Hypertension: 2026 ACC Expert Consensus Decision Pathway: A Report of the American College of Cardiology Solution Set Oversight Committee - link

Journal of Antimicrobial Chemotherapy
- Oxazolidinones in the Clinical Management of Staphylococcal Infection—Linezolid or Tedizolid? A review on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS) - link

Journal of General Internal Medicine
- Does Intensive Therapy Targeting Modifiable Risk Factors Prevent Diabetic Neuropathy in Adults with Type 2 Diabetes? A Systematic Review and Meta-analysis of Randomized Clinical Trials - link

Journal of Hospital Infection
- Evaluation of preventive interventions addressing healthcare-associated infections and antimicrobial resistance: a systematic review – link

- Global randomised controlled trials in infection prevention and control: a bibliographic review from the past two decades - link

Lancet
- 14-day versus 28-day trifluridine–tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan - link

Lancet Diabetes & Endocrinology
- Disease modification outcomes in type 2 diabetes: a modified Delphi - link
- The development of obesity pharmacotherapy: from early challenges and setbacks to recognition by WHO - link

Lancet Infectious Diseases
- Effectiveness of respiratory syncytial virus immunisation in practice - link

Lancet Psychiatry
- Change in HbA1c and weight after initiation of antipsychotic treatment in people with severe mental illness in England: an individual-level interrupted time-series analysis - link
- GLP-1 receptor agonist initiation and risk of psychiatric hospitalisation and emergency department presentation in adults with schizophrenia and type 2 diabetes in the USA: an observational cohort study using electronic health records data - link

New England Journal of Medicine
- Continuous Glucose Monitoring in Non–Insulin-Treated Type 2 Diabetes - link
- Ponatinib–Blinatumomab or Imatinib–Chemotherapy for Adult Ph-Positive ALL - link
- Adult Attention Deficit–Hyperactivity Disorder - link
- Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea - link
- Ianalumab for the Treatment of Patients with Sjögren's Disease - link
- Helicobacter pylori Infection — Advances, Challenges, and the Road Ahead - link
- Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis - link
- Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis - link
- Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC - link
- Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer - link
- Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy - link
- Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy - link
- Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial - link
- Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC - link
- Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer - link
- Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer - link

Pediatric Quality & Safety
- Achieving Faster Bleeding Disorder Treatment in the Emergency Department: A Quality Improvement Initiative – link
- Impact of a Quality Improvement Initiative to Reduce Medication-induced Kidney Injury – link
- Quality Improvement Initiative: Implementation of a Unified Pediatric Asthma Pathway Reduces Critical Care Requirements - link

Pediatrics (American Academy of Pediatrics)
- Recommendations for Prevention and Control of Influenza in Children, 2026–2027: Technical Report - link
- Recommendations for Prevention and Control of Influenza in Children, 2026–2027: Policy Statement - link
- Recommendations for the Prevention of Respiratory Syncytial Virus Disease in Infants and Children: Policy Statement - link

- Recommendations for the Prevention of Respiratory Syncytial Virus Disease in Infants and Children: Technical Report - link
- Immunogenicity and Safety of PHH-1V COVID-19 Vaccine as a Heterologous Booster in Adolescents - link
- Vaccine-Induced Antibody and T Cell Immunity to Measles and Varicella in Children With ALL - link
- Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents, 2026–2027: Policy Statement - link
- Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents, 2026–2027: Technical Report - link

Pharmacotherapy
- A Model for Estimating the Risk of Gastrointestinal Bleeding for Patients on Oral Anticoagulants and Interacting Medications - link
- Incremental Predictive Value of Dynamic Platelet-to-Lymphocyte Ratio Beyond ESR and CRP for Glucocorticoid Sparing in Rheumatoid Arthritis: A Multi-Center Retrospective Cohort Study - link

CONSULTATIONS

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Pilot of the NSQHS Standards (third edition) – closes 20 November 2026 - link

TGA
- Consultation: High-moderate risk changes to permissible ingredients - Vitamin B6 (pyridoxine hydrochloride, pyridoxal 5-phosphate, and pyridoxal 5-phosphate monohydrate) - Closes on 25 November 2026 - link

WEBINARS & PODCASTS

Australian Prescriber Podcasts
- E225 | Glaucoma management in adults: an update

MJA Podcasts
- Building better bone health - link

Purple Pen Podcast
- PPP 198 - Pins, Needles, and Too Much Vitamin B6

UPCOMING EVENTS

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Registrations open – National Medicines Symposium NMS 2026, ‘Medicines stewardship: safer use starts with all of us’ - Wednesday, 11 November 2026 - register - program